▴ Daptomycin is a lipopeptide antibacterial with rapid in vitro activity against Gram-positive cocci. It is approved for use in patients with complicated skin and skin structure infections (cSSSIs) caused by specified Gram-positive cocci.
▴ In vitro, daptomycin was active against Staphylococcus aureus (including meticillin-resistantstrains), Streptococcus pyogenes, S. agalactiae, group C and G β-haemolytic streptococci and vancomycin-susceptible Enterococcus faecalis. Bactericidal activity in vitro was rapid and concentration dependent.
▴ In two randomised, investigator-blinded, multicentre trials in patients with cSSSIs, intravenous daptomycin 4 mg/kg once daily was as effective as standard therapy (intravenous semi-synthetic penicillin 4–12 g/day or vancomycin 1g 12-hourly). Clinical success rates assessed 6–20 days after treatment end were 82.1% in daptomycin recipients and 82.9% in recipients of standard therapy (pooled data).
▴ In patients with cSSSIs, the adverse event profiles of daptomycin and vancomycin were similar. Creatine phosphokinase (CPK) levels increased in 2.8% of daptomycin recipients and 1.8% of patients who received standard therapy; only one daptomycin recipient (0.2%) experienced increased CPK levels and muscle symptoms that were not associated with any comorbid factors.
KeywordsMinimum Inhibitory Concentration Linezolid Teicoplanin Daptomycin Clinical Success Rate
- 2.FDA US Food and Drug Administration. FDA talk paper: FDA approves first in new class of antibiotic [online]. Available from URL: http://www.fda.gOv//bbs/topics/ANSWERS/2003/ANS01252.html [Accessed 2003 Sep 25]
- 5.Cubist Pharmaceuticals. Cubicin (daptomycin for injection) full prescribing information [online]. Available from URL: http://www.cubicin.com/fullprescribingl.htm [Accessed 2003 Oct 3]
- 10.Hanberger H, Nilsson LE, Maller R, et al. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 1991 Sep; 35(9): 1710–6PubMedCrossRefGoogle Scholar
- 13.National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A 6. 6th ed. Wayne (PA): National Committee for Clinical Laboratory Standards, 2003Google Scholar
- 14.Fluit AC, Milatovic D, Verhoef J. Activity of daptomycin, a novel lipopeptide, against European Gram-positive cocci [abstract no. E-527]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago, 174Google Scholar
- 15.Klein JD, Ludlam E, Steele-Moore L. In vitro activity of ABT-773, telithromycin and daptomycin against group C and G Streptococci [abstract no. E-1894]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego, 167Google Scholar
- 19.Petersen PJ, Bradford PA, Weiss WJ, et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002 Aug; 46(8): 2595–601PubMedCrossRefGoogle Scholar
- 20.Jones ME, Draghi DC, Critchley IA, et al. In vitro activity of daptomycin against a prospective collection of European enterococci [abstract plus poster P812]. 12th European Congress of Clinical Microbiology and Infectious Diseases; 2002 Apr 24–27; MilanGoogle Scholar
- 22.Snydman DR, McDermott LA, Jacobus NV. Determination of synergistic effects of daptomycin with gentamicin or in vitro effect of beta-lactam antibiotics against S. aureus and enterococci by FIC index and time-kill kinetics [abstract no. E-533]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago, 175Google Scholar
- 27.Rand K, Houck H. Daptomycin synergy with oxacillin against methicillin resistant Staphylococcuc aureus (MRSA) [abstract no. C-091]. 103rd Annual Meeting of American Society for Microbiology; 2003 18–22 May; Washington, DCGoogle Scholar
- 33.Rybak M, McKinnon P, Cha R, et al. Daptomycin pharmacodynamics versus MRSA at various doses as assessed by a Monte Carlo prediction model [abstract no. A-2195]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago, 37Google Scholar
- 34.Safdar N, Andes DR, Craig WA. In-vivo pharmacodynamics of daptomycin [abstract no. 72]. Clin Infect Dis 1999 Oct; 29(4): 974Google Scholar
- 36.Kaatz GW, Seo SM. Analysis of the mechanism(s) of daptomycin resistance in Staphylococcus aureus [abstract no. CI-1803]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago, 99Google Scholar
- 45.Dvorchik B, Sica D, Gehr T. Pharmacokinetics (PK) and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease [abstract no. A-1387]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San DiegoGoogle Scholar
- 46.Campanaro ES, Talley FP, Eisenstein BI, et al. Comparison of efficacy and safety of daptomycin (DAP) versus semi-synthetic penicillin (SSP) and vancomycin (VAN) in patients with complicated skin and skin structure infections (cSSSI) [abstract no. L-737 plus poster DapIV-0209]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago [abstracts on disk]Google Scholar
- 47.Roditi D, Arbeit RD. Clinical significance of dual infection with Staphylococcus aureus and hemolytic streptococci in complicated skin and soft tissue infections: results from Daptomycin Trial 99-01 [abstract no. L-1482]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago, 471Google Scholar
- 48.Matthews PP, Debruin MF. Faster resolution of clinical signs in complicated skin and soft tissue infections by daptomycin vs standard therapy in a randomised, blinded, comparative study [abstract no. 112]. Clin Infect Dis 2001 Oct; 33(7): 1107Google Scholar
- 49.Knapp AG, Tally FP, Arbeit RD. Skeletal muscle effects in patients receiving once-daily daptomycin (DAP) for complicated skin and skin structure infections (cSSSI) [abstract no. L-736 plus poster DAPIV-0214]. 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago [abstracts on disk]Google Scholar